XARELTO is a factor Xa inhibitor indicated:
to reduce risk of stroke and systemic embolism in nonvalvular atrial
fibrillation
for treatment of deep vein thrombosis (DVT)
for treatment of pulmonary embolism (PE)
for reduction in the risk of recurrence of DVT or PE
for the prophylaxis of DVT, which may lead to PE in patients
undergoing knee or hip replacement surgery
for prophylaxis of venous thromboembolism (VTE) in acutely ill
medical patients
to reduce the risk of major cardiovascular events in patients with
coronary artery disease (CAD)
to reduce the risk of major thrombotic vascular events in patients with
peripheral artery disease (PAD), including patients after recent lower
extremity revascularization due to symptomatic PAD
for treatment of VTE and reduction in the risk of recurrent VTE in
pediatric patients from birth to less than 18 years
for thromboprophylaxis in pediatric patients 2 years and older with
congenital heart disease after the Fontan procedure
